Per a court order, HHS is required to restore this website to its version as of 12:00 AM on January 29, 2025. Information on this page may be modified and/or removed in the future subject to the terms of the court’s order and implemented consistent with applicable law. Any information on this page promoting gender ideology is extremely inaccurate and disconnected from truth. The Trump Administration rejects gender ideology due to the harms and divisiveness it causes. This page does not reflect reality and therefore the Administration and this Department reject it.

U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion

Guidance Document: Antibacterial Therapies for Patients with an Unmet Medical Need for the Treatment of Serious Bacterial Diseases

About this resource:

HHS Non-systematic Review

Source: Food and Drug Administration, 2017

Last Reviewed: August 2018

Workgroups: Food Safety Workgroup

This webpage gives an overview of guidance on clinical development of new antibacterial drugs. Specifically, the guidance is for sponsors who are developing new antibacterial drugs to treat serious bacterial diseases in patients with unmet medical needs. It also includes links to:

  • The federal register notice
  • Full guidance document
  • Public comments on the guidance
Read more about this resource

Objectives related to this resource (2)

Prevent an increase in the proportion of nontyphoidal Salmonella infections that are resistant to multiple drug classes — FS‑05
Baseline only
Prevent an increase in the proportion of macrolide antibiotic-resistant Campylobacter infections — FS‑06
Baseline only

Suggested Citation

1.

U.S. Food and Drug Administration. (2017). Antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases. Retrieved from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/antibacterial-therapies-patients-unmet-medical-need-treatment-serious-bacterial-diseases